GWM
AZN icon

GSB Wealth Management’s AstraZeneca AZN Stock Holding History

GSB Wealth Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-7,462
Closed -$509K – 55
2017
Q2 		$509K Hold
7,462
– – 2.3% 11
2017
Q1 		$465K Hold
7,462
– – 1.97% 16
2016
Q4 		$408K Buy
+7,462
New +$424K 1.6% 20

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

GSB Wealth Management's AZN Position: Q3 2017 in Review

GSB Wealth Management sold out of AstraZeneca (AZN) in Q3 2017, closing a stake of 7,462 shares — an estimated $509K sold.

GSB Wealth Management first reported a position in AZN in Q4 2016 and held it in 3 quarters. The position peaked at $509K in Q2 2017. 455 funds tracked by Wall St. Rank hold AZN as of Q3 2017.

  • GSB Wealth Management reported no remaining AstraZeneca position as of Q3 2017 after selling out during the quarter.
  • GSB Wealth Management sold 7,462 AstraZeneca shares in Q3 2017, an estimated $509K.
  • GSB Wealth Management first reported a position in AstraZeneca in Q4 2016 and held it in 3 quarters.
  • GSB Wealth Management's AstraZeneca position peaked at $509K in Q2 2017.
  • 455 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2017.

Based on GSB Wealth Management's 13F filing for Q3 2017, filed 24 Nov 2017.